Trails Edge Capital Partners LP Invests $29.30 Million in BioMarin Pharmaceutical Inc. $BMRN

Trails Edge Capital Partners LP acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 512,000 shares of the biotechnology company’s stock, valued at approximately $29,296,640. BioMarin Pharmaceutical comprises 0.0% of Trails Edge Capital Partners LP’s investment portfolio, making the stock its 6th biggest holding. Trails Edge Capital Partners LP owned approximately 0.26% of BioMarin Pharmaceutical at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of BMRN. CIBC Private Wealth Group LLC increased its holdings in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC raised its position in BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after purchasing an additional 183 shares during the last quarter. Caerus Investment Advisors LLC lifted its position in BioMarin Pharmaceutical by 2.8% in the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock valued at $608,000 after acquiring an additional 278 shares in the last quarter. Chicago Partners Investment Group LLC grew its stake in shares of BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock worth $660,000 after acquiring an additional 290 shares during the period. Finally, Parallel Advisors LLC increased its stake in BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 295 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN traded down $0.62 on Friday, hitting $64.67. The stock had a trading volume of 1,098,354 shares, compared to its average volume of 2,066,778. The firm has a 50-day moving average of $61.50 and a 200-day moving average of $58.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98. The company has a market capitalization of $12.52 billion, a price-to-earnings ratio of 174.78, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company’s revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BMRN. Piper Sandler lifted their price objective on BioMarin Pharmaceutical from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. UBS Group set a $88.00 price target on BioMarin Pharmaceutical in a report on Wednesday. HC Wainwright lowered their price target on shares of BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating for the company in a report on Tuesday, August 18th. The Goldman Sachs Group assumed coverage on BioMarin Pharmaceutical in a research note on Monday, May 11th. They set a “neutral” rating and a $69.00 price objective on the stock. Finally, BMO Capital Markets initiated coverage on BioMarin Pharmaceutical in a research report on Wednesday, August 19th. They set an “outperform” rating and a $98.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.79.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.